RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Drug discovery company SCYNEXIS, Inc. today announced that supportive data from a preclinical study of the Company’s lead product candidate for hepatitis C (HCV), SCY-635, will be presented in a poster session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in Boston, MA, October 30-November 3, 2009. SCYNEXIS plans to initiate a Phase 2a combination trial of SCY-635 in patients with HCV in the second quarter of 2010. SCY-635 is a non-immunosuppressive cyclosporin analog that has demonstrated potent suppression of plasma viremia when given as monotherapy to adults with chronic hepatitis C virus infection.
